Innovative immunobiotechnology for recombinant cytokine drug forms development

S A Ketlinsky; A S Simbirtsev; A M Ischenko

Medical academic journal ›› 2009, Vol. 9 ›› Issue (4) :75 -82.

Articles

research-article

Innovative immunobiotechnology for recombinant cytokine drug forms development

Author information +

History +

Abstract

Cytokines represent a new regulatory system existing alongside with the neuroendocrine regulation and aimed for the body homeostasis regulation during pathogen invasion and tissue damage. During past three decades genes of major cytokines were cloned and biologically active recombinant analogues were synthesized. Future of the cytokine therapy is connected with the recombinant molecules obtained using modern immunobiotechnology. Several new recombinant cytokine drug forms for clinical use are developed in the State Research Institute of Highly Pure Biopreparations, including that of interferon alpha 2b, mterleukin-1 beta and interleukin-1 receptor antagonist. Among them human recombinant interleukin-1 beta (Betaleukin) is registered for clinical use only in Russia. New IL-1 drug forms include ointments, geles, biodegradable sponges for therapy of Patients with burns, infected wounds, trophic ulcers. Use of IL-1 ointment for trophic ulcers therapy in patients with diabetes e to high healing efficacy and allowed to avoid amputation. Recombinant interferon alpha aerosol drug form is used for the erapy of patients with acute viral respiratory infections including influenza. Aerosolized interferon application decreased ness duration for 2-3 days.This clinical result could give very big economical effect in the whole country. In general topical cytokine application has several advantages including high local drug concentration in the desired organ, and absence of systemic adverse effects. Nowadays cytokines are widely used for the therapy of infectious diseases, immunodeficiency and activ t^ FUrt' 1er development of this therapeutic direction will give new highly effective drugs with enhanced pharmacological

Keywords

immunobiotechnologys / cytokines / drug forms

Cite this article

Download citation ▾

S A Ketlinsky, A S Simbirtsev, A M Ischenko. Innovative immunobiotechnology for recombinant cytokine drug forms development. Medical academic journal, 2009, 9(4): 75-82 DOI:

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Симбирцев А.С. Цитокины - новая система регуляции защитных реакций организма // Цитокины и воспаление. 2002. Т. 1. № 1. С. 9-17.

[2]	Кетлинский С.А., Симбирцев А.С. Цитокины. СПб.: Фолиант, 2008. 552 с.

[3]	Симбирцев А.С. Новые подходы к клиническому применению рекомбинантного интерлейкина-1 бета человека//Мед. иммунол. 1999. Т. 1. № 1-2. С. 141-146.

[4]	Петров СВ., Симбирцев А.С, Бубнова Н.А. и др. Использование интерлейкина-1(3 для местного лечения больных с трофическими язвами нижних конечностей венозной этиологии // Мед. иммунол. 2001. Т. 3.№4. С. 533-539.

[5]	Варюшина Е.А., Москаленко В.В., Симбирцев А.С. и др. Ранозаживляющее и местное иммуностимулирующее действие рекомбинантного интерлейкина-1 бета человека при применении у больных с длительно незаживающими ранами и трофическими язвами // Цитокины и воспаление. 2007. Т. 6. № 2. С. 54-62.

[6]	Варюшина Е.А., Москаленко В.В., Лебедева Т.П. и др. Использование интерлейкина-1 бета для местного лечения гнойно-некротических поражений нижних конечностей // Мед. иммунол. 2008. Т. 10. № 4-5. С. 439-448.

[7]	Ischenko A., Nikolaev В., Kotova Т. et al. IL-1 receptor antagonist as an aerosol in inflammation // J. Aerosol. Med. 2007. Vol. 20. № 4. P. 445-459.